Drugs Made In America Acquisition II Corp. Fair Value Disclosure
NOTE 8 — FAIR VALUE MEASUREMENTS
The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
| Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |
| Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |
| Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
The following table presents information about the Company’s financial instruments that are measured at fair value as of December 31, 2025 and September 26, 2025 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. There were no assets or liabilities measured at fair value as of December 31, 2024.
| Level | December 31, 2025 | |||||||
| Assets: | ||||||||
| Cash and investments held in Trust Account | 1 | $ | 504,933,800 | |||||
| Liabilities: | ||||||||
| Over-allotment option | 3 | $ | ||||||
| Level | September 26, 2025 | |||||||
| Assets: | ||||||||
| Cash and investments held in Trust Account | 1 | $ | 500,000,000 | |||||
| Liabilities: | ||||||||
| Over-allotment option | 3 | $ | 553,748 | |||||
| Equity: | ||||||||
| Fair value of Public Rights for ordinary shares subject to possible redemption allocation | 3 | $ | 10,355,000 | |||||
The over-allotment option was accounted for as a liability in accordance with ASC 815-40 and was presented within liabilities on the balance sheet. The over-allotment option liability is measured at fair value at inception and on a recurring basis, with changes in fair value presented within changes in fair value of over-allotment option liability in the statement of operations.
The following table presents the change in the recurring Level 3 fair value of the over-allotment option liability:
Over-allotment Option Liability | ||||
| Balance – January 1, 2025 | $ | |||
| Establish over-allotment option liability at September 26, 2025 | 553,748 | |||
| Change in fair value | (553,748 | ) | ||
| Balance – December 31, 2025 | $ | |||
The Company used a Black-Scholes model to value the over-allotment option. The over-allotment option liability was classified within Level 3 of the fair value hierarchy at the measurement dates due to the use of unobservable inputs inherent in pricing models are assumptions related to expected share-price volatility, expected life and risk-free interest rate. The Company estimates the volatility of its ordinary shares based on historical volatility that matches the expected remaining life of the option. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the option. The expected life of the option is assumed to be equivalent to their remaining contractual term.
The key inputs into the Black-Scholes model were as follows at initial measurement of the over-allotment option:
| September 26, 2025 | ||||
| Risk-free interest rate | 4.20 | % | ||
| Expected term (years) | 0.12 | |||
| Expected volatility | 3.12 | % | ||
| Exercise price | $ | 10.00 | ||
The underwriters’ over-allotment option expired on November 8, 2025. As such, the over-allotment option liability was reduced to $0 as of December 31, 2025.
The fair value of the Public Rights issued in the Initial Public Offering is $10,355,000, or $0.2071 per Public Right. The Public Rights have been classified within shareholders’ deficit and will not require remeasurement after issuance. The Public Rights were classified within Level 3 of the fair value hierarchy at the measurement dates due to the use of unobservable inputs inherent in assumptions related to the market adjustments as noted below. The following table presents the quantitative information regarding market assumptions used in the valuation of the Public Rights:
| September 26, 2025 | ||||
| Trade price of Unit | $ | 10.00 | ||
| Stock price | $ | 9.793 | ||
| Market adjustment | 21.1 | % | ||
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.